Table 3. Relationship between docetaxel neutropaenic sensitivity (Slope in μg−1 ml) and patients’ covariates.
| Models | Mean (±95% CI) | IIV Slope (%) | ΔOBJa | P-values |
|---|---|---|---|---|
| Intermediate model | ||||
| Slope=θ1(AGE/60.7)θ2(AAG/1.29)θ3 θ4PTT2θ5CEN | θ1=7.91 (±1.64) θ2=−0.68 (±1.01) θ3=−0.74 (±0.18)θ4=1.48 (±0.45) θ5=1.77 (±0.49) | 44 | −5 | NS |
| Final model | ||||
| Slope=θ1(AGE/1.29)θ2θ3PTT2θ4CEN | θ1=7.40 (±1.22) θ2=−0.72 (±0.18) θ3=1.69 (±0.32) θ4=1.82 (±0.46) | 44 | — | — |
| Alternative models | ||||
| Slope=θ1(AAG/1.29)θ2θ3CEN | θ1=7.73 (±1.45) θ2=−0.80 (±0.27) θ3=1.88 (±0.62) | 52 | +39 | <0.001 |
| Slope=θ1(AAG/1.29)θ2θ3PTT2 | θ1=7.86 (±1.39) θ2=−0.51 (±0.27) θ3=−1.94 (±0.58) | 59 | +46 | <0.001 |
| Slope=θ1θ2PTT2θ3CEN | θ1=7.5 (±1.4) θ2=1.42 (±0.69) θ3=2.15 (±0.75) | 57 | +71 | <0.001 |
AAG=serum α1-acid glycoprotein level; CEN=0 or=1 if data corresponded to Paris or Toulouse, respectively; CI=confidence interval; IIV=interindividual variability; NS=nonsignificant; PTT2=0 or=1 if patient received less than two lines, or at least two lines of chemotherapy before docetaxel, respectively.
a
Difference in objective function value in comparison with final covariate model.